Collagen type II

Collagen (type II)/Drug Interactions:

  • AntiarthriticsAntiarthritics: In animal and human research, oral administration of cartilage-derived type II collagen has been shown to reduce symptoms of arthritis (7; 18; 8). Theoretically, concurrent use may have additive effects.
  • EstrogensEstrogens: Experimental treatment with hormone replacement therapy (HRT), such as estradiol, in humans resulted in decreased collagen type II levels (10; 11).
  • HepatotoxinsHepatotoxins: In human studies, patients taking type II collagen exhibited elevated transaminase levels (7; 8). Theoretically, concurrent use with hepatotoxic agents may increase the risk of liver damage.
  • ImmunosuppressantsImmunosuppressants: According to human and laboratory research, type II collagen may have immunosuppressive effects (12; 13; 14; 15; 16; 17; 8). Theoretically, concurrent use may increase the risk of immunosuppression.

    • Collagen (typeII)/Herb/SupplementInteractions:

  • AntiarthriticsAntiarthritics: In animal and human research, oral administration of cartilage-derived type II collagen has been shown to reduce symptoms of arthritis (7; 18; 8). Theoretically, concurrent use may have additive effects.
  • HepatotoxinsHepatotoxins: In human studies, patients taking type II collagen exhibited elevated transaminase levels (7; 8). Theoretically, concurrent use with hepatotoxic agents may increase the risk of liver damage.
  • ImmunomodulatorsImmunomodulators: According to human and laboratory research, type II collagen may have immunosuppressive effects (12; 13; 14; 15; 16; 17; 8). Theoretically, concurrent use may increase the risk of immunosuppression.
  • PhytoestrogensPhytoestrogens: Experimental treatment with HRT, such as estradiol, in humans resulted in decreased collagen type II levels (10; 11).

    • Collagen (type II)/Food Interactions:

  • Insufficient available evidence.

    • Collagen (typeII)/LabInteractions:

  • CreactiveproteinC-reactiveprotein: It is unclear whether type II collagen elevates the levels of C-reactive protein (7).
  • CtelopeptidefragmentsoftypeIIcollagenC-telopeptidefragmentsoftypeIIcollagen: Levels of urinary C-telopeptide fragments of type II collagen (CTX-II) were elevated 104% in rheumatoid arthritis (RA) patients compared with the levels in healthy controls (19). High baseline levels of urinary carboxy-terminal cross-linking telopeptide of type I collagen (CTX-I) and CTX-II independently predicted an increased risk of radiologic progression over four years in patients with early RA, especially those without radiologic joint damage (3).
  • HemoglobinHemoglobin: In human research, type II collagen administration caused a nonsignificant decrease in hemoglobin (8).
  • PlateletcountPlateletcount: In human research, type II collagen administration caused a nonsignificant decrease in platelet count (8).
  • TransaminaselevelsTransaminaselevels: In human studies, patients taking type II collagen exhibited elevated transaminase levels (7; 8). The highest transaminase level reported was an alanine aminotransferase value of 583 IU.
  • WhitebloodcellsWhitebloodcells: In human research, type II collagen administration caused a significant decrease in white blood cell count and a nonsignificant decrease in neutrophil count (8).

    • Collagen/NutrientDepletion:

  • HormonereplacementtherapyHRTHormonereplacementtherapy (HRT): Experimental treatment with HRT, such as estradiol, in humans resulted in decreased collagen type II levels (10; 11).